Back to Search Start Over

Structure and function analysis of an antibody recognizing all influenza A subtypes

Authors :
Kallewaard, Nicole L.
Corti, Davide
Collins, Patrick J.
Neu, Ursula
McAuliffe, Josephine M.
Benjamin, Ebony
Wachter-Rosati, Leslie
Palmer-Hill, Frances J.
Yuan, Andy Q.
Walker, Philip A.
Vorlaender, Matthias K.
Bianchi, Siro
Guarino, Barbara
De Marco, Anna
Vanzetta, Fabrizia
Agatic, Gloria
Foglierini, Mathilde
Pinna, Debora
Fernandez-Rodriguez, Blanca
Fruehwirth, Alexander
Silacci, Chiara
Ogrodowicz, Roksana W.
Martin, Stephen R.
Sallusto, Federica
Suzich, JoAnn A.
Lanzavecchia, Antonio
Zhu, Qing
Gamblin, Steven J.
Skehel, John J.
Kallewaard, Nicole L.
Corti, Davide
Collins, Patrick J.
Neu, Ursula
McAuliffe, Josephine M.
Benjamin, Ebony
Wachter-Rosati, Leslie
Palmer-Hill, Frances J.
Yuan, Andy Q.
Walker, Philip A.
Vorlaender, Matthias K.
Bianchi, Siro
Guarino, Barbara
De Marco, Anna
Vanzetta, Fabrizia
Agatic, Gloria
Foglierini, Mathilde
Pinna, Debora
Fernandez-Rodriguez, Blanca
Fruehwirth, Alexander
Silacci, Chiara
Ogrodowicz, Roksana W.
Martin, Stephen R.
Sallusto, Federica
Suzich, JoAnn A.
Lanzavecchia, Antonio
Zhu, Qing
Gamblin, Steven J.
Skehel, John J.
Publication Year :
2021

Abstract

Influenza virus remains a threat because of its ability to evade vaccine-induced immune responses due to antigenic drift. Here, we describe the isolation, evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively reacting with all influenza A hemagglutinin (HA) subtypes. MEDI8852 uses the heavy-chain VH6-1 gene and has higher potency and breadth when compared to other anti-stem antibodies. MEDI8852 is effective in mice and ferrets with a therapeutic window superior to that of oseltamivir. Crystallographic analysis of Fab alone or in complex with H5 or H7 HA proteins reveals that MEDI8852 binds through a coordinated movement of CDRs to a highly conserved epitope encompassing a hydrophobic groove in the fusion domain and a large portion of the fusion peptide, distinguishing it from other structurally characterized cross- reactive antibodies. The unprecedented breadth and potency of neutralization by MEDI8852 support its development as immunotherapy for influenza virus-infected humans.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1240539488
Document Type :
Electronic Resource